Article

Patient outcomes and intraoperative use of phenylephrine/ketorolac 1%/0.3%

Author(s):

Julianne Mobilian
Conferences|ASCRS

ICYMI: Denise Visco, MD, shares the take-home message from her 2019 ASCRS presentation.

Denise Visco, MD, conducted a retrospective chart analysis of patients who received phenylephrine and ketorolac (OMIDRIA) during surgery-here's what she found.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
Related Content
Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
May 18th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
May 11th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

EyePod
June 17th 2020

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Subretinal drusenoid deposits: Marker for unrecognized cardiac disease
May 6th 2025

Subretinal drusenoid deposits: Marker for unrecognized cardiac disease

(Image credit: AdobeStock/Roman)
April 30th 2025

ASCRS 2025: Visual and patient-reported outcomes following bilateral Odyssey implantation

© 2025 MJH Life Sciences

All rights reserved.